Statera Biopharma Inc

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Live Conference Call and Webcast at 5:30 p.m. ET

Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the closing of its previously announced underwritten public offering of 12,555,555 units (“Units”), at a price to the public of $0.45 per Unit for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Each Unit consists of one share of common stock, par value $0.005 per share (the “Common Stock”), one warrant with a one-year term to purchase one share of Common Stock at an exercise price of $0.45 per share (the “One-Year Warrants”), and one warrant with a five-year term to purchase one share of our Common Stock at an exercise price of $0.5625 per share (the “Five-Year Warrants”). The shares of Common Stock, the One-Year Warrants, and the Five-Year Warrants are immediately separable and will be issued separately and uncertificated. In connection with the offering, the underwriters have partially exercised their option to purchase an additional 1,883,333 One-Year Warrants and 1,883,333 Five-Year Warrants at the public offering price of $0.01 per One-Year Warrant and $0.01 per Five-Year Warrant, less the underwriting discount per warrant, solely to cover over-allotments, if any.

Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the pricing of its underwritten public offering of approximately 10,843,721 units (“Units”), at a price to the public of $0.45 per Unit and approximately 1,716,666 pre-funded units (the “Pre-funded Units”), at a price to the public of $0.44 per Pre-Funded Unit, for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Each Unit consists of one share of common stock, par value $0.005 per share (the “Common Stock”), one warrant with a one-year term to purchase one share of Common Stock at an exercise price of $0.45 per share (the “One-Year Warrants”), and one warrant with a five-year term to purchase one share of our Common Stock at an exercise price of $0.5625 per share (the “Five-Year Warrants”). The shares of Common Stock, the One-Year Warrants, and the Five-Year Warrants are immediately separable and will be issued separately and uncertificated. Each Pre-Funded Unit will consist of one pre-funded warrant to purchase one share of Common Stock (“Pre-Funded Warrant”), one One-Year Warrant, and one Five-Year Warrant. The purchase price of each Pre-Funded Unit will equal the price per Unit being sold to the public in this offering, minus $0.01, and the exercise price of each Pre-Funded Warrant will equal $0.01 per share of Common Stock.

Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, on March 21, 2022, announced it has commenced an underwritten public offering. This press release corrects certain deal terms that were in the prior press release.

CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced it has commenced an underwritten public offering.

Statera Biopharma Announces Proposed Underwritten Public Offering

FORT COLLINS, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced revised unaudited, preliminary financial results for its Fiscal Year ended December 31, 2021.

Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021

In collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200

Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 Platform

Grab Holdings Ltd

VEON

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 4th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 4th, 2022

Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19) Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)

CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

—Satish Chandran of Lays Sciences and Physis Pharma, Inc. to join Board of Directors as Steve Barbarick transitions to advisory role—

Statera Biopharma Announces Changes to Board of Directors

FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced unaudited, preliminary revenue and other financial results for its Fiscal Year ended December 31, 2021.

Statera Biopharma Announces Preliminary Revenue and Financial Results of Fiscal Year ‘21

STAT-201 is being developed as a novel, immune-modulation therapy  for treating Crohn's Disease

Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn's Disease

FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the closing of its previously announced registered direct offering with a certain institutional investor, pursuant to which the Company sold $2.0 million worth of its common stock and warrants.

Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering

Statera Biopharma Inc STAB has announced a registered direct offering of $2 million common stock and warrants. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Statera Biopharma Shares Tumble After Raising $2M Via Equity

The stock price of Statera Biopharma, Inc. (NASDAQ: STAB) fell by over 15% pre-market today. This is why it happened.

Statera Biopharma (STAB) Stock: Why The Price Substantially Fell Today

FORT COLLINS, Colo., Feb. 06, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that it entered into a securities purchase agreement with a certain institutional investor to purchase approximately $2.0 million worth of its common stock and warrants in a registered direct offering.

Statera Biopharma Announces Pricing of $2.0 Million Registered Direct Offering

Company developing STAT-201 as a novel therapy for immune modulation in treating pediatric patients with Crohn's Disease Company developing STAT-201 as a novel therapy for immune modulation in treating pediatric patients with Crohn's Disease

Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn's Disease

Initial Study to Evaluate P harmacokinetics, Biomarkers and Safety of STAT-205

Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

Modifications to Entolimod clinical trial protocol in acute radiation syndrome enable continued program development Modifications to Entolimod clinical trial protocol in acute radiation syndrome enable continued program development

Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod

Statera Biopharma's (STAB) CEO Michael K. Handley on Q3 2021 Results - Earnings Call Transcript

Management to Host Conference Call Today, Monday, November 15, 2021, 5:30 p.m. ET Management to Host Conference Call Today, Monday, November 15, 2021, 5:30 p.m. ET

Statera Biopharma Provides Third Quarter 2021 Financial and Corporate Update

Management to Host Conference Call on Monday, November 15, 2021, at 5:30 p.m. ET Management to Host Conference Call on Monday, November 15, 2021, at 5:30 p.m. ET

Statera Biopharma, Inc. to Report Third Quarter 2021 Financial Results

Company developing STAT-401 as adjunct therapy to extend the duration of disease remission in patients with pancreatic cancer Company developing STAT-401 as adjunct therapy to extend the duration of disease remission in patients with pancreatic cancer

Statera Biopharma Honors Pancreatic Cancer Awareness Month

Researchers at Loma Linda University Health to Evaluate P harmacokinetics, Biomarkers and Safety of STAT-205

News for Statera Biopharma Inc Stock (STAB)